| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2018: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2017: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2016: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
|
|---|
| Outline of Final Research Achievements |
Despite recent improvements in therapeutic options, pharmacotherapy for abdominal aortic aneurysm (AAA) has yet to be achieved. We have investigated the role of focal adhesion kinase (FAK), a major mediator of integrin signaling pathways, in the pathogenesis of AAA. We found that FAK was highly activated in AAA wall specimens. Activated FAK was mostly localized to macrophages in the AAA walls. FAK inhibitor PF573228 significantly reduced levels of inflammatory molecules. We created the mouse model of AAA by periaortic application of CaCl2. Treatment of mice with PF573228 significantly reduced inflammatory cell infiltration and disruption of the elastic lamellae, and prevented the progression of AAA. FAK represents a novel therapeutic target for the treatment of AAA.
|
